Raphael J. Mannino - 14 Dec 2021 Form 4 Insider Report for Matinas BioPharma Holdings, Inc. (MTNB)

Role
Chief Scientific Officer
Signature
/s/ Keith A. Kucinski
Issuer symbol
MTNB
Transactions as of
14 Dec 2021
Net transactions value
$0
Form type
4
Filing time
15 Dec 2021, 20:22:17 UTC
Previous filing
14 Sep 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MTNB Stock Option (right to Buy) Award $0 +275,000 $0.000000 275,000 14 Dec 2021 Common Stock 275,000 $0.9200 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 14, 2022 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2022.